Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer

• Published in: Cancer Vol. 130; no. 7; pp. 1061 - 1071
• Main Authors: Hinchcliff, Emily M., Knisely, Anne, Adjei, Naomi, Fellman, Bryan, Yuan, Ying, Patel, Ami, Xu, Cai, Westin, Shannon N., Sood, Anil K., Soliman, Pamela T., Shafer, Aaron, Fleming, Nicole D., Gershenson, David M., Vikram, Raghunandan, Bathala, Tharakeswara, Vining, David, Ganeshan, Dhakshina M., Lu, Karen H., Sun, Charlotte C., Meyer, Larissa A., Jazaeri, Amir A.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.04.2024
• Subjects: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Bayes Theorem; Bayesian analysis; Cancer; Cytotoxicity; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lymphocytes; Monoclonal antibodies; Ovarian cancer; Ovarian Neoplasms - drug therapy; Patients; Platinum; Targeted cancer therapy; ovarian neoplasms; immune checkpoint inhibitors; patient-reported outcome measures; immunotherapy; randomized controlled trial
• ISSN: 0008-543X; 1097-0142; 1097-0142
• DOI: 10.1002/cncr.35126

There was no difference in the median progression‐free survival for combination tremelimumab plus durvalumab compared to tremelimumab alone (administered as part of a sequential treatment strategy) in a heavily pretreated population of patients with platinum‐resistant high‐grade serous ovarian cancer. The adverse event profile was consistent with that previously reported for immune checkpoint blockade, and patient‐reported outcomes were similar in both arms.